NCT04774926 - Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab. | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

October 15, 2021

Primary Completion Date

October 4, 2023

Study Completion Date

October 4, 2023

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG

Brolucizumab

120 mg/ml solution for intravitreal injection

Trial Locations (20)

10126

Novartis Investigative Site, Torino

20100

Novartis Investigative Site, Milan

20122

Novartis Investigative Site, Milan

20123

Novartis Investigative Site, Milan

20132

Novartis Investigative Site, Milan

20900

Novartis Investigative Site, Monza

34129

Novartis Investigative Site, Trieste

35128

Novartis Investigative Site, Padua

37024

Novartis Investigative Site, Negrar

40138

Novartis Investigative Site, Bologna

50134

Novartis Investigative Site, Florence

53100

Novartis Investigative Site, Siena

60126

Novartis Investigative Site, Ancona

70021

Novartis Investigative Site, Acquaviva delle Fonti

80131

Novartis Investigative Site, Napoli

80138

Novartis Investigative Site, Napoli

09124

Novartis Investigative Site, Cagliari

00133

Novartis Investigative Site, Roma

00144

Novartis Investigative Site, Roma

00168

Novartis Investigative Site, Roma